[go: up one dir, main page]

SI2596807T1 - Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj - Google Patents

Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj

Info

Publication number
SI2596807T1
SI2596807T1 SI200731744T SI200731744T SI2596807T1 SI 2596807 T1 SI2596807 T1 SI 2596807T1 SI 200731744 T SI200731744 T SI 200731744T SI 200731744 T SI200731744 T SI 200731744T SI 2596807 T1 SI2596807 T1 SI 2596807T1
Authority
SI
Slovenia
Prior art keywords
treatment
agents useful
ocular disorders
complement binding
binding aptamers
Prior art date
Application number
SI200731744T
Other languages
English (en)
Inventor
David Epstein
Jeffrey C. Kurz
Original Assignee
Archemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Llc filed Critical Archemix Llc
Publication of SI2596807T1 publication Critical patent/SI2596807T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SI200731744T 2006-03-08 2007-03-08 Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj SI2596807T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78090506P 2006-03-08 2006-03-08
US84827406P 2006-09-29 2006-09-29
EP12173138.4A EP2596807B1 (en) 2006-03-08 2007-03-08 Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
SI2596807T1 true SI2596807T1 (sl) 2016-03-31

Family

ID=38475591

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731744T SI2596807T1 (sl) 2006-03-08 2007-03-08 Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
SI200731599T SI1991275T1 (sl) 2006-03-08 2007-03-08 Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731599T SI1991275T1 (sl) 2006-03-08 2007-03-08 Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj

Country Status (21)

Country Link
US (2) US20090269356A1 (sl)
EP (5) EP2596807B1 (sl)
JP (3) JP5406534B2 (sl)
KR (3) KR101513308B1 (sl)
CN (1) CN104623692A (sl)
AU (1) AU2007223796B2 (sl)
BR (1) BRPI0708588A2 (sl)
CA (4) CA3009854A1 (sl)
DK (2) DK2596807T3 (sl)
ES (2) ES2527695T3 (sl)
HK (1) HK1225996A1 (sl)
HU (1) HUE026496T2 (sl)
IL (1) IL193828A (sl)
MX (1) MX2008011323A (sl)
NZ (1) NZ571791A (sl)
PL (2) PL2596807T3 (sl)
PT (2) PT2596807E (sl)
RU (2) RU2477137C2 (sl)
SG (3) SG172686A1 (sl)
SI (2) SI2596807T1 (sl)
WO (1) WO2007103549A2 (sl)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR20100072185A (ko) * 2007-09-24 2010-06-30 녹손 파르마 아게 씨파이브에이 결합형 핵산
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
BRPI0820343A2 (pt) 2007-11-08 2017-08-22 Genentech Inc Anticorpos de antifator b e seus usos
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9891219B2 (en) 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US20120065254A1 (en) * 2009-03-23 2012-03-15 Noxxon Pharma Ag C5A binding nucleic acids and the use thereof
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
US9408746B2 (en) 2010-03-31 2016-08-09 Ocuject, Llc Device and method for intraocular drug delivery
US9320647B2 (en) 2010-03-31 2016-04-26 Ocuject, Llc Device and method for intraocular drug delivery
JPWO2012070618A1 (ja) 2010-11-24 2014-05-19 株式会社カネカ 増幅核酸検出方法及び検出デバイス
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
AU2013201627B2 (en) * 2011-04-08 2016-02-11 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2012157479A1 (ja) 2011-05-13 2012-11-22 国立大学法人 東京大学 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
AP2014007761A0 (en) 2011-12-21 2014-07-31 Novartis Ag Compositions and methods for antibodies targeting factor P
MX362061B (es) 2012-01-10 2019-01-07 Noxxon Pharma Ag Ácidos nucleicos de enlace c5a nuevos.
EP2807192B1 (en) 2012-01-27 2018-04-18 Abbvie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
US9421129B2 (en) 2012-04-02 2016-08-23 Ocuject, Llc Intraocular delivery devices and methods therefor
US9504603B2 (en) 2012-04-02 2016-11-29 Ocuject, Llc Intraocular delivery devices and methods therefor
US9783844B2 (en) * 2012-04-27 2017-10-10 Kaneka Corporation Method for amplifying nucleic acid and method for detecting amplified nucleic acid
PT2861246T (pt) * 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
KR20150036481A (ko) 2012-07-12 2015-04-07 노파르티스 아게 보체 경로 조절제 및 그의 용도
KR102712879B1 (ko) 2012-07-13 2024-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
EP2904014A4 (en) 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
CN105143261B (zh) * 2013-01-31 2021-04-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法
WO2014160129A2 (en) 2013-03-14 2014-10-02 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2014160958A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EP3019243A4 (en) 2013-07-12 2017-03-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
HRP20210013T1 (hr) * 2013-08-28 2021-04-02 Ipc Research, Llc Stabilni polipeptidi koji se vezuju za ljudski komplement c5
JP6654137B2 (ja) * 2013-09-16 2020-02-26 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
US20160237146A1 (en) * 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
US10392652B2 (en) 2013-11-22 2019-08-27 Kaneka Corporation Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end
EP3086809A4 (en) 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP3102708B1 (en) * 2014-02-05 2020-11-18 Deakin University Aptamer construct
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3194596A1 (en) * 2014-09-16 2017-07-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016048388A1 (en) 2014-09-26 2016-03-31 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
HUE061076T2 (hu) 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
IL259256B2 (en) * 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP2019506159A (ja) 2016-01-20 2019-03-07 ヴィトリサ セラピューティクス， インコーポレイテッド Ｄ因子を阻害するための組成物および方法
JP2019508405A (ja) * 2016-02-08 2019-03-28 ヴィトリサ セラピューティクス， インコーポレイテッド 改良された硝子体内半減期を有する組成物およびその使用
CN109310760A (zh) 2016-06-07 2019-02-05 诺华股份有限公司 抗c5抗体给药方案
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
DK3525583T3 (da) 2016-10-12 2025-10-27 Bioverativ Usa Inc Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CN110603054B (zh) 2017-03-06 2024-05-10 宾夕法尼亚大学理事会 抗c5抗体及其用途
WO2019040397A1 (en) * 2017-08-21 2019-02-28 Ophthotech Corporation METHOD FOR TREATING OR PREVENTING MACULAR DEGENERATION OF THE NEOVASCULAR AGE
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
EP3597222A1 (en) * 2018-07-16 2020-01-22 Easemedcontrol R & D GmbH & Co KG Treatment and diagnosis of unresolved inflammatory diseases
MX2021002710A (es) 2018-09-06 2021-09-23 Univ Pennsylvania Anticuerpos anti-c5 humanizados y usos de los mismos.
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4048288A4 (en) * 2019-10-27 2023-11-29 IVERIC bio, Inc. ANTI-C5 AGENT FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD
US20220411799A1 (en) * 2019-10-28 2022-12-29 National University Of Singapore DNMT1-Specific Aptamers and Production and Uses Thereof
RU2738001C1 (ru) * 2020-03-23 2020-12-07 Борис Сергеевич Першин Способ определения риска развития цитомегаловирусного (ЦМВ) ретинита после трансплантации гемопоэтических стволовых клеток
CN118234749A (zh) 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
WO2023183556A2 (en) * 2022-03-24 2023-09-28 Amcyte Pharma, Inc. Treatment for retinal disorders
JP2025515485A (ja) * 2022-04-29 2025-05-15 アネクソン，インコーポレーテッド 眼の疾患を治療するための組成物及び方法
KR20250031151A (ko) 2022-06-30 2025-03-06 아스텔라스 유에스 엘엘씨 안과적 병태를 치료하기 위한 지속 방출 실리카 히드로겔 복합재 및 이를 사용하는 방법
EP4587572A2 (en) * 2022-09-16 2025-07-23 Sirnaomics, Inc. Products and compositions
CN119019553B (zh) * 2024-09-18 2025-09-23 广州博富瑞医学检验有限公司 一种抗补体蛋白c5的抗体及其用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5981481A (en) 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4959309A (en) * 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3546806C2 (sl) * 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5648214A (en) 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5726017A (en) * 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5252216A (en) 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5338671A (en) * 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE69431290D1 (de) * 1993-02-12 2002-10-10 Avant Immunotherapeutics Inc PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
US5428149A (en) * 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
RU2073518C1 (ru) * 1993-06-17 1997-02-20 Совместное русско-американское акционерное общество закрытого типа "Неофарм" Средство, восстанавливающее функцию сетчатой оболочки глаза
WO1995001797A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation Protein purification
US5817635A (en) 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5723750A (en) * 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
EP0828849B1 (en) 1995-06-02 2006-10-25 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to pdgf
AU726844B2 (en) * 1995-06-07 2000-11-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PT957929E (pt) 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
ATE300957T1 (de) * 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
AU4028800A (en) 1999-04-02 2000-10-23 City Of Hope Method for identifying accessible binding sites on rna
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20020099884A1 (en) 2001-01-19 2002-07-25 Chang William Ho Output controller systems and method for universal data output
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US7595430B2 (en) * 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
AU2003294437A1 (en) * 2002-11-21 2004-06-18 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
WO2004050899A2 (en) * 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2’-substituted nucleic acids
EP1606301A4 (en) * 2003-01-21 2006-06-14 Archemix Corp APTAMERIC THERAPEUTICS FOR MEDICINAL THERAPY FOR EYES
EP2281885A1 (en) * 2003-08-27 2011-02-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
ES2674129T3 (es) * 2004-02-12 2018-06-27 Archemix Llc Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
WO2005084412A2 (en) * 2004-03-05 2005-09-15 Archemix Corp. Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX2007016561A (es) * 2005-06-30 2008-03-10 Archemix Corp Materiales y metodos para la generacion de transcriptos de acido nucleico completamente modificados en la posicion 2.
US7564805B1 (en) 2005-08-08 2009-07-21 At&T Intellectual Property, Ii, L.P. Systems, methods, and device for simulating capacity in a network
US9119701B2 (en) 2012-10-22 2015-09-01 Alcon Research, Ltd. Pressure control in phacoemulsification system
CN106662625B (zh) 2014-08-18 2019-12-03 马格内蒂卡有限责任公司 用于头和手足成像的磁体

Also Published As

Publication number Publication date
SG10201706440RA (en) 2017-09-28
CA3009846C (en) 2021-08-31
JP2014172910A (ja) 2014-09-22
KR20080100388A (ko) 2008-11-17
KR101584468B1 (ko) 2016-01-13
CA3148917A1 (en) 2007-09-13
PT1991275E (pt) 2015-02-03
PT2596807E (pt) 2016-03-18
EP3034094A1 (en) 2016-06-22
EP2596807A1 (en) 2013-05-29
EP1991275B1 (en) 2014-11-05
RU2012153978A (ru) 2014-06-20
PL2596807T3 (pl) 2016-06-30
JP2013067661A (ja) 2013-04-18
HK1181308A1 (en) 2013-11-08
RU2477137C2 (ru) 2013-03-10
ES2527695T3 (es) 2015-01-28
WO2007103549A3 (en) 2007-12-27
JP2009529058A (ja) 2009-08-13
DK1991275T3 (en) 2014-12-08
SI1991275T1 (sl) 2015-03-31
CN104623692A (zh) 2015-05-20
KR20140072219A (ko) 2014-06-12
WO2007103549A2 (en) 2007-09-13
NZ571791A (en) 2012-03-30
EP1991275A4 (en) 2009-07-08
KR20150017388A (ko) 2015-02-16
JP5406534B2 (ja) 2014-02-05
HK1127281A1 (en) 2009-09-25
EP2596807B1 (en) 2015-12-16
SG2014011290A (en) 2014-06-27
AU2007223796B2 (en) 2013-01-24
EP3360582A1 (en) 2018-08-15
HUE026496T2 (en) 2016-06-28
PL1991275T3 (pl) 2015-04-30
HK1225996A1 (en) 2017-09-22
CA3009854A1 (en) 2007-09-13
EP4159220A1 (en) 2023-04-05
BRPI0708588A2 (pt) 2011-06-07
AU2007223796A1 (en) 2007-09-13
SG172686A1 (en) 2011-07-28
US20090269356A1 (en) 2009-10-29
EP1991275A2 (en) 2008-11-19
IL193828A0 (en) 2009-08-03
CA2643951C (en) 2019-03-05
MX2008011323A (es) 2008-11-18
CA3009846A1 (en) 2007-09-13
JP5746232B2 (ja) 2015-07-08
US20170145416A1 (en) 2017-05-25
ES2562423T3 (es) 2016-03-04
RU2008139901A (ru) 2010-04-20
KR101513308B1 (ko) 2015-04-28
DK2596807T3 (en) 2016-03-07
CA2643951A1 (en) 2007-09-13
IL193828A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
SG10201706440RA (en) Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
IL195819A0 (en) Modulators of metabolism and the treatment of disorders related thereto
ZA200900055B (en) Modulators of metabolism and the treatment of disorders related thereto
SI2374472T1 (sl) Sestavki in postopki za zdravljenje oftalmoloških motenj
LT3385384T (lt) Aptamero terapija, naudinga su komplementu susijusių ligų gydymui
PL2390255T3 (pl) Nowe aminoglikozydy i ich zastosowania w leczeniu zaburzeń genetycznych
EP2094281A4 (en) USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES OR OCULAR DISORDERS
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
ZA200807620B (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
PL2374472T3 (pl) Kompozycje i sposoby leczenia zaburzeń okulistycznych
GB0513413D0 (en) The treatment of inflammatory disorders and pain
GB0622476D0 (en) The treatment of inflammatory disorders and pain
GB0609794D0 (en) The treatment of inflammatory disorders and pain
IL229577A (en) Amino-sugars and their use to treat genetic diseases
IL244653B (en) New amino-sugars and their use for the treatment of genetic diseases
GB0502596D0 (en) The treatment of inflammatory disorders and pain
GB0722524D0 (en) The treatment of inflammatory disorders and pain
GB0703494D0 (en) The treatment of inflammatory disorders and pain
GB0711769D0 (en) The treatment of inflammatory disorders and pain
GB0718279D0 (en) The treatment of inflammatory disorders and pain
SI1727567T1 (sl) Aptamerni terapevtiki, uporabni v zdravljenju s komplementom povezanih motenj
IL194370A0 (en) Novel aminoglycosides and uses thereof in the treatment of genetic disorders